Literature DB >> 24944382

Analgesia with ibuprofen arginate versus conventional ibuprofen for patients with dysmenorrhea: a crossover trial.

Donald R Mehlisch1, Alfredo Ardia2, Teresa Pallotta2.   

Abstract

BACKGROUND: Dysmenorrhea produces painful abdominal cramps that can disrupt the personal lives and productivity of women.
OBJECTIVE: The aim of this study was to compare the analgesic efficacy, including onset and duration of pain relief, peak effect, and total effect, and tolerability of ibuprofen arginate with those of conventional ibuprofen in patients with moderate to severe pain associated with primary dysmenorrhea.
METHODS: Patients were administered a single dose of ibuprofen arginate (200 or 400 mg), conventional ibuprofen (200 or 400 mg), or placebo during each of 5 menstrual cycles in a single-center, double-blind, randomized, double-dummy, 5-cycle, crossover study. Patients recorded their pain intensity and pain relief at regularly scheduled intervals (10, 20, 30, 40, 50, 60, and 90 minutes and 2, 3, 4, 5, and 6 hours) after taking the study medication, and all study observations were recorded in a patient diary. Pain intensity was rated using the following 4-point categoric rating scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Pain relief was rated on a 5-point scale as 0 = none, 1 = a little, 2 = some, 3 = a lot, and 4 = complete relief. Tolerability of ibuprofen arginate was based on a comparison of the incidence of spontaneously reported adverse events in each of the treatment groups.
RESULTS: One hundred four patients entered the study. Of these, 81.7% were white; the mean (SD) age was 27.5 (5.0) years. A total of 65.4% of patients reported moderate pain from dysmenorrhea, and the remaining 34.6% reported severe pain; 20.2% of patients did not complete the study. The median time to achieve meaningful pain relief was ∼30 minutes faster with ibuprofen arginate 400 mg than with either dose of conventional ibuprofen. Tolerability was similar across all treatments.
CONCLUSIONS: In this study population of patients experiencing acute pain as a result of primary dysmenorrhea, ibuprofen arginate was associated with effective, tolerable analgesia and a more rapid onset of action than conventional ibuprofen. The faster onset of analgesia may have a role in clinical practice in treating women with dysmenorrhea. A faster onset of action may be important to women whose personal relationships, productivity, or ability to sleep is being adversely affected by pain.

Entities:  

Keywords:  dysmenorrhea; ibuprofen; pain management; randomized, doubleblind, placebo-controlled clinical trial

Year:  2003        PMID: 24944382      PMCID: PMC4053012          DOI: 10.1016/S0011-393X(03)00104-8

Source DB:  PubMed          Journal:  Curr Ther Res Clin Exp        ISSN: 0011-393X


  17 in total

1.  Double-blind crossover comparison of ketoprofen, naproxen, and placebo in patients with primary dysmenorrhea.

Authors:  D R Mehlisch
Journal:  Clin Ther       Date:  1990 Sep-Oct       Impact factor: 3.393

2.  Ketoprofen, ibuprofen, and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison.

Authors:  D R Mehlisch
Journal:  J Clin Pharmacol       Date:  1988-12       Impact factor: 3.126

3.  Absorption, distribution and toxicity of ibuprofen.

Authors:  S S Adams; R G Bough; E E Cliffe; B Lessel; R F Mills
Journal:  Toxicol Appl Pharmacol       Date:  1969-09       Impact factor: 4.219

4.  Feldene in the symptomatic treatment of primary dysmenorrhoea.

Authors:  H C Cash; D Humpston; H S Kasap
Journal:  Practitioner       Date:  1982-07

5.  Arginine infusion blocks the action of parathyroid hormone but not arginine vasopressin on the renal tubule in man.

Authors:  D S O'Reilly; W D Fraser; M D Penney; F C Logue; R A Cowan; B C Williams; G Walters
Journal:  J Endocrinol       Date:  1986-12       Impact factor: 4.286

6.  High nocturnal body temperatures and disturbed sleep in women with primary dysmenorrhea.

Authors:  F C Baker; H S Driver; G G Rogers; J Paiker; D Mitchell
Journal:  Am J Physiol       Date:  1999-12

7.  A controlled comparative study of ibuprofen arginate versus conventional ibuprofen in the treatment of postoperative dental pain.

Authors:  Donald R Mehlisch; Alfredo Ardia; Teresa Pallotta
Journal:  J Clin Pharmacol       Date:  2002-08       Impact factor: 3.126

8.  Ibuprofen arginate provides effective relief from postoperative dental pain with a more rapid onset of action than ibuprofen.

Authors:  Paul Desjardins; Peter Black; Maria Papageorge; Tom Norwood; Danny D Shen; Lonnie Norris; Alfredo Ardia
Journal:  Eur J Clin Pharmacol       Date:  2002-08-02       Impact factor: 2.953

Review 9.  Update on ibuprofen: review article.

Authors:  M Busson
Journal:  J Int Med Res       Date:  1986       Impact factor: 1.671

10.  A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain.

Authors:  Peter Black; Mitchell B Max; Paul Desjardins; Thomas Norwood; Alfredo Ardia; Teresa Pallotta
Journal:  Clin Ther       Date:  2002-07       Impact factor: 3.393

View more
  5 in total

Review 1.  Dysmenorrhoea.

Authors:  Michelle L Proctor; Cynthia M Farquhar
Journal:  BMJ Clin Evid       Date:  2007-03-01

Review 2.  Dysmenorrhoea.

Authors:  Pallavi Manish Latthe; Rita Champaneria; Khalid Saeed Khan
Journal:  BMJ Clin Evid       Date:  2011-02-21

Review 3.  Nonsteroidal anti-inflammatory drugs for dysmenorrhoea.

Authors:  Jane Marjoribanks; Reuben Olugbenga Ayeleke; Cindy Farquhar; Michelle Proctor
Journal:  Cochrane Database Syst Rev       Date:  2015-07-30

4.  The effects of fish oil capsules and vitamin B1 tablets on duration and severity of dysmenorrhea in students of high school in Urmia-Iran.

Authors:  A Hosseinlou; V Alinejad; M Alinejad; N Aghakhani
Journal:  Glob J Health Sci       Date:  2014-09-18

5.  Development of Pelubiprofen Tromethamine with Improved Gastrointestinal Safety and Absorption.

Authors:  Ji Yeon Park; Dong Ho Oh; Sang-Wook Park; Bo Ram Chae; Chul Woo Kim; Sang Heon Han; Hyeon Jong Shin; Soo Bin Yeom; Da Yeong Lee; Min Kyu Park; Sang-Eun Park; Jun-Bom Park; Kyung-Tae Lee
Journal:  Pharmaceutics       Date:  2021-05-18       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.